title: Molecular insight and pharmacological approaches targeting mitochondrial dynamics in skeletal muscle during obesity.
abstract: Obesity-associated insulin resistance is the major characteristic of the early stage of metabolic syndrome. A decline in mitochondrial function plays a role in the development of insulin resistance in obesity and type 2 diabetes. Accumulating data reveal that mitochondrial dynamics, the balance between mitochondrial fusion and fission, are an important factor in the maintenance of mitochondrial function. Thus, the mechanisms underlying the regulation of mitochondrial dynamics in obesity deserve further investigation. This review describes an overview of mitochondrial fusion and fission machineries, and discusses the mechanistic and functional aspects of mitochondrial dynamics, with a focus on skeletal muscle in obesity. Finally, we discuss current pharmacological approaches of targeting mitochondrial dynamics. Elucidating the role of mitochondrial dynamics in skeletal muscle afflicted by obesity may provide not only important clues in understanding muscle insulin resistance, but also new therapeutic targets.
authors: Institute of Clinical Medicine.
authors: Huei-Fen
authors: HF
authors: Jheng
authors: Institute of Clinical Medicine.
authors: Shin-Han
authors: SH
authors: Huang
authors: Institute of Clinical Medicine.
authors: Hsueh-Maio
authors: HM
authors: Kuo
authors: Institute of Clinical Medicine.|International Research Center of Wound Repair and Regeneration.
authors: Michael W
authors: MW
authors: Hughes
authors: Institute of Clinical Medicine.|Research Center of Clinical Medicine, National Cheng Kung University Hospital, Tainan, Taiwan, Republic of China.
authors: Yau-Sheng
authors: YS
authors: Tsai
mesh_terms: D000818:Animals; D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007333:Insulin Resistance; D008931:Mitochondria, Muscle / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D028361:Mitochondrial Diseases / Q000209:etiology / Q000517:prevention & control*; D063154:Mitochondrial Dynamics / Q000187:drug effects*; D024101:Mitochondrial Proteins / Q000235:genetics / Q000378:metabolism; D058990:Molecular Targeted Therapy; D018482:Muscle, Skeletal / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D009765:Obesity / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D018384:Oxidative Stress / Q000187:drug effects; D011499:Protein Processing, Post-Translational / Q000187:drug effects
chemical_list: D019440:Anti-Obesity Agents; D007004:Hypoglycemic Agents; D024101:Mitochondrial Proteins
keywords: insulin resistance; lipid accumulation; mitochondrial morphology; posttranslational modification; skeletal muscle